• Home
• About Us
  • Anergis Vision
  • Management team
  • Board of directors
  • Scientific advisory board
• Technology
  • Ultra-fast AIT
  • COP Technology
  • Intellectual Property
  • Publications
• Pipeline
  • Product Pipeline
  • Aller T Birch
  • Aller R Ragweed
  • Aller DM Dust Mites
• News
• Contact

• Home>
• News

News

07 Sep 2017	Anergis Announces Top Line Results from Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT
13 Jun 2017	T-cell responses after COP Immunotherapy to be Presented at EAACI Congress 2017
01 Mar 2017	Anergis to Present Dose-Dependent Immunological Effects of Ultra-Fast Allergy Immunotherapy AllerT at the AAAAI annual meeting
08 Feb 2017	Anergis Completes Patient Recruitment in Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT
24 Jan 2017	Anergis Appoints Klaus Schollmeier as New Chairman of the Board of Directors
07 Jun 2016	Anergis to Present New Data on AllerT at the 35th EAACI Congress 2016
04 Apr 2016	Anergis Closes CHF 5 Million Financing Round Extension to Conduct Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT
04 Jun 2015	Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015
02 Jun 2015	Anergis Appoints Kim Simonsen as Chief Development Officer
01 Apr 2015	Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial

Page 1 of 5

• 1
• 2
• 3
• 4
• 5
• End

Anergis

• Clinical-stage biopharmaceutical company based in Switzerland
• Ultra-Fast Allergy Immunotherapy

About Us

• Anergis Vision
• Management team
• Board of directors
• Scientific advisory board

Technology

• Ultra-fast AIT
• COP Technology
• Intellectual Property
• Publications

Contact

• Biopôle III, Route de la Corniche 9B
  CH-1066 Epalinges
• Email: